- Study participant is diagnosed with any form of Parkinsonism other than idiopathic PD (eg, atypical or secondary Parkinsonism) - Study participant is diagnosed with dementia or has important cognitive dysfunction, as determined by Montreal Cognitive Assessment (MoCA) <23 at screening - Study participant has a history of neurosurgical intervention for PD (including DBS, thalamotomy, and experimental cell therapy or gene therapy) - Participant has a severe peak dose or biphasic dyskinesia at screening, defined by Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) items 4.2 score 4 or as per investigator opinion - Participant has a history of major depression or psychotic disorder or any other psychiatric condition within the past 5 years, that, as per investigator opinion, could jeopardize or would compromise the study participant’s ability to participate in the study - Study participant has a history of narrow angle glaucoma - Study participant has a history of melanoma - Study participant has current untreated hypertension - Study participant has a history of hypertensive crisis and/or hypertensive encephalopathy, unless the underlying cause was unequivocally identified and has been removed - Study participant has orthostatic hypotension requiring medication or a current history of “clinically significant” orthostatic hypotension as per the investigator’s opinion (eg, recurrent orthostatic presyncope or syncope) - Study participant has a history over the past 12 months or between the Screening and Baseline Visits of any clinically significant arrythmia, myocardial infarction, stroke, transient ischemic attack, moderate or severe congestive heart failure (either New York Heart Association Class III or IV or known ejection fraction <40%)